ADMA Biologics (ADMA) Q1 2026 earnings review
Margin Explosion Masked by a Top-Line Brick Wall
ADMA’s Q1 results present a severe narrative break. While gross margins surged to a stellar 71% and ASCENIV revenues grew 28%, the total top-line flatlined at $114.5M, completely missing the hyper-growth trajectory of previous quarters. The core issue: BIVIGAM sales collapsed 54% amid aggressive standard IG market discounting and distributor inventory resets. Even more alarming, management slashed their FY26 revenue guidance by roughly $90 million and outright withdrew their long-term growth targets. While an internal probe into channel stuffing allegations cleared the company, the timing of delayed purchase orders and gutted guidance leaves a heavy shadow over the near-term story.
🐂 Bull Case
Despite zero top-line growth, gross margins expanded dramatically to 71% from 53% last year. Adjusted Net Income grew 22% to $40.7M, and the company generated a massive $58M in operating cash flow.
The high-margin specialty product ASCENIV delivered 28% YoY growth, hitting record utilization levels and proving resilient against the discounting pressures plaguing the standard IG market.
🐻 Bear Case
Slashing FY26 revenue targets by 14% and completely withdrawing the '>$1.1B pre-2030' target destroys the prevailing bull thesis. A 'temporary dislocation' should not require abandoning long-term multi-year guidance.
BIVIGAM revenue fell 54%. ADMA has limited pricing power in the standard IG market, which is currently flooded with raw material plasma and competitive discounting.
⚖️ Verdict: 🔴
Bearish. The margin profile and cash generation are spectacular, but the catastrophic guidance cut and the complete withdrawal of long-term targets indicate management has lost visibility into their own market. The growth premium previously attached to this stock will likely evaporate until top-line momentum returns.
Key Themes
BIVIGAM Collapse and Macro Reset
Reversing. After quarters of steady contribution, BIVIGAM revenue plummeted 54% YoY to $15.4M. Management cited a macro reset in the U.S. IG market driven by elevated raw material plasma supply, increased competitive inventories, and aggressive discounting. This structural oversupply has removed ADMA's pricing leverage in the standard IG tier.
Guidance Contradictions
Decelerating. Management labeled Q1 as a 'trough revenue baseline' caused by a 'temporary market dislocation.' However, their actions contradict this optimism: they permanently withdrew their long-term financial guidance and slashed FY26 revenue guidance from $635M to $545M (midpoint). If the issue is truly temporary, long-term targets for 2029 should remain intact. This discrepancy is a major red flag for investors.
Channel Stuffing Probe and Order Timing
Stable. The Audit Committee, aided by independent forensic accountants, found no evidence of illegal activity or improper channel stuffing. However, management separately noted that 'late-quarter inventory dynamics shifted certain contractual purchase orders anticipated for March into early April.' While officially cleared, the sudden shift in order timing immediately following whistleblower allegations will draw intense scrutiny regarding the underlying quality of historical revenue beats.
Margin Profile Transformation
Accelerating. The solitary bright spot in the print is profitability. Gross margin rocketed to 71%, up from 53% in 25Q1. This was driven by a favorable mix shift (higher-margin ASCENIV replacing lower-margin BIVIGAM) and the successful realization of the FDA-approved yield-enhanced manufacturing process implemented in late 2025.
ASCENIV Growth Continues
Stable. ASCENIV grew 28% YoY to $97.5M. The product’s positioning as a later-line therapy for complex immunodeficient patients successfully insulated it from the discounting wars occurring in the broader standard IG market. Prescriber breadth and patient adherence metrics remain at record levels.
Aggressive Capital Returns
Accelerating. Buoyed by $58M in operating cash flow, ADMA exited Q1 with net leverage below 0.5x. Through March 2026, the company actively executed on its Accelerated Share Repurchase (ASR) program, converting approximately 3.7% of its total outstanding share count into treasury stock.
Other KPIs
Accelerating. Up 68% from $26.9M in 25Q1. However, this includes a one-time $8.0M pre-tax gain from the divestiture of three plasma collection centers. Adjusted Net Income, which strips out this gain, grew a more modest 22% to $40.7M.
Accelerating. A massive sequential and YoY improvement, demonstrating the power of the 71% gross margin. This cash conversion allowed the company to comfortably fund share buybacks and end the quarter with $138.1M in cash.
Accelerating. Up significantly from $0.8M in 25Q1. This directly reflects the planned R&D investments to advance the SG-001 hyperimmune globulin program through its clinical pathways.
Guidance
Decelerating. A massive downward revision from the $635M target provided just three months prior. Assuming FY25 revenue finished around $510.5M, the new midpoint ($545M) implies a meager ~6.7% YoY growth rate, ending ADMA's era of hyper-growth.
Decelerating. Cut from the prior expectation of $360M. While the raw number is lower due to the revenue haircut, the implied EBITDA margin at the midpoint sits at a healthy 51.8%, protecting the bottom-line floor.
Decelerating. Slashed from the previous $255M target, primarily reflecting the lost BIVIGAM sales volume. This implies essentially flat YoY growth compared to implied FY25 actuals.
Key Questions
Long-Term Guidance Withdrawal
If the current U.S. IG market pricing dislocation is truly 'temporary' as stated in the release, why did management feel compelled to completely withdraw the pre-2030 $1.1B revenue target rather than simply delay it?
Quantifying the Order Shift
Can you quantify the exact dollar amount of contractual purchase orders that slipped from March into April? How much of the flat YoY revenue result was structural versus simple timing?
BIVIGAM Price Floor
With the standard IG market flooded with raw material plasma and heavy discounting, at what price point does it make sense to halt BIVIGAM production entirely and reallocate all resources to ASCENIV?
McKesson Agreement Dynamics
How does the new McKesson Specialty distribution agreement alter the company's historical channel inventory levels, and did the transition to this agreement play a role in the Q1 ordering disruptions?